China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Capital Reinvestment Ratio
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Capital Reinvestment Ratio of 0.39x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥487.90 Million) in capital expenditures (CN¥192.28 Million). See debt-free asset ratio of China Resources Double-Crane Pharmaceuti to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China Resources Double-Crane Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2024)
This chart tracks China Resources Double-Crane Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Check 600062 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for China Resources Double-Crane Pharmaceutical Co Ltd (1999–2024)
Year-by-year Capital Reinvestment Ratio for China Resources Double-Crane Pharmaceutical Co Ltd from 1999 to 2024. For live market cap and broader valuation context, see 600062 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | CN¥1.83 Billion | CN¥637.50 Million | ▼ -6.1% |
| 2023 | 0.37x | CN¥1.65 Billion | CN¥614.31 Million | ▼ -5.0% |
| 2022 | 0.39x | CN¥1.34 Billion | CN¥525.53 Million | ▲ +6.8% |
| 2021 | 0.37x | CN¥1.34 Billion | CN¥491.67 Million | ▲ +43.3% |
| 2020 | 0.26x | CN¥1.36 Billion | CN¥348.09 Million | ▲ +52.5% |
| 2019 | 0.17x | CN¥1.44 Billion | CN¥241.65 Million | ▲ +7.8% |
| 2018 | 0.16x | CN¥1.47 Billion | CN¥228.69 Million | ▲ +19.4% |
| 2017 | 0.13x | CN¥1.19 Billion | CN¥154.82 Million | ▼ -8.6% |
| 2016 | 0.14x | CN¥771.25 Million | CN¥110.04 Million | ▼ -40.6% |
| 2015 | 0.24x | CN¥701.35 Million | CN¥168.49 Million | ▲ +21.2% |
| 2014 | 0.20x | CN¥718.38 Million | CN¥142.38 Million | ▼ -50.3% |
| 2013 | 0.40x | CN¥546.24 Million | CN¥217.68 Million | ▼ -28.9% |
| 2012 | 0.56x | CN¥396.05 Million | CN¥221.89 Million | ▼ -15.4% |
| 2011 | 0.66x | CN¥511.53 Million | CN¥338.78 Million | ▼ -8.8% |
| 2010 | 0.73x | CN¥509.67 Million | CN¥370.18 Million | ▼ -12.9% |
| 2009 | 0.83x | CN¥342.01 Million | CN¥285.16 Million | ▼ -10.6% |
| 2008 | 0.93x | CN¥331.71 Million | CN¥309.20 Million | ▲ +61.2% |
| 2007 | 0.58x | CN¥235.46 Million | CN¥136.17 Million | ▲ +2.3% |
| 2006 | 0.57x | CN¥303.71 Million | CN¥171.66 Million | ▼ -37.9% |
| 2005 | 0.91x | CN¥139.78 Million | CN¥127.13 Million | ▲ +109.7% |
| 2004 | 0.43x | CN¥453.72 Million | CN¥196.84 Million | ▼ -82.8% |
| 2003 | 2.52x | CN¥148.94 Million | CN¥375.98 Million | ▲ +40.9% |
| 2002 | 1.79x | CN¥140.63 Million | CN¥251.99 Million | ▲ +43.9% |
| 2001 | 1.25x | CN¥141.01 Million | CN¥175.58 Million | ▲ +147.8% |
| 2000 | 0.50x | CN¥172.81 Million | CN¥86.83 Million | ▼ -5.4% |
| 1999 | 0.53x | CN¥131.54 Million | CN¥69.86 Million | — |